Day One Biopharmaceuticals Stock Buy Hold or Sell Recommendation

DAWN Stock  USD 11.82  0.36  2.96%   
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Day One Biopharmaceuticals is 'Cautious Hold'. The recommendation algorithm takes into account all of Day One's available fundamental, technical, and predictive indicators you will find on this site.
  
Check out Day One Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
In addition, we conduct extensive research on individual companies such as Day and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

Execute Day One Buy or Sell Advice

The Day recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Day One Biopharmaceuticals. Macroaxis does not own or have any residual interests in Day One Biopharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Day One's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Day OneBuy Day One
Cautious Hold

Market Performance

Very WeakDetails

Volatility

Not too volatileDetails

Hype Condition

Low keyDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

AverageDetails

Economic Sensitivity

Slowly supersedes the marketDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

FrailDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Day One Biopharmaceuticals has a Mean Deviation of 1.83, Standard Deviation of 2.25 and Variance of 5.04
Our trade advice tool can cross-verify current analyst consensus on Day One Biopharmaceu and to analyze the company potential to grow in the current economic cycle. To make sure Day One is not overpriced, please confirm all Day One Biopharmaceu fundamentals, including its current ratio, and the relationship between the net income and target price . Given that Day One Biopharmaceu has a number of shares shorted of 17.29 M, we urge you to verify Day One Biopharmaceuticals market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Day One Trading Alerts and Improvement Suggestions

Day One Biopharmaceu generated a negative expected return over the last 90 days
Day One Biopharmaceu has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (188.92 M) with profit before overhead, payroll, taxes, and interest of 99.66 M.
Day One Biopharmaceuticals currently holds about 394.86 M in cash with (146.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.38.
Day One Biopharmaceu has a frail financial position based on the latest SEC disclosures
Over 95.0% of the company shares are held by institutions such as insurance companies
Latest headline from businesswire.com: DAWN fordert Internationalen Strafgerichtshof auf, Ermittlungen gegen die Biden-Regierung wegen Beihilfe zu israelischen Kriegsverbrechen in Gaza einzuleiten

Day One current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Day analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Day analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Day One Returns Distribution Density

The distribution of Day One's historical returns is an attempt to chart the uncertainty of Day One's future price movements. The chart of the probability distribution of Day One daily returns describes the distribution of returns around its average expected value. We use Day One Biopharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Day One returns is essential to provide solid investment advice for Day One.
Mean Return
-0.12
Value At Risk
-3.28
Potential Upside
3.92
Standard Deviation
2.25
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Day One historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Day Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument, such as Day One, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Day One Biopharmaceuticals back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
Shares
Alyeska Investment Group, L.p.2024-12-31
2.5 M
Timessquare Capital Management, Llc2024-12-31
1.7 M
T. Rowe Price Associates, Inc.2024-12-31
1.7 M
Geode Capital Management, Llc2024-12-31
1.5 M
Vestal Point Capital Lp2024-12-31
1.4 M
Hhg Plc2024-12-31
1.3 M
Boxer Capital Llc2024-09-30
1.2 M
Marshall Wace Asset Management Ltd2024-12-31
1.1 M
Morgan Stanley - Brokerage Accounts2024-12-31
1.1 M
Fmr Inc2024-12-31
12.9 M
Blackrock Inc2024-12-31
6.2 M
Note, although Day One's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Day One Cash Flow Accounts

202020212022202320242025 (projected)
Change In Cash16.4M240.6M(199.0M)145.5M167.4M175.7M
Free Cash Flow(13.6M)(56.5M)(109.9M)(150.1M)(135.1M)(128.3M)
Other Non Cash Items30.0M8M(2.0M)(7.1M)(6.4M)(6.1M)
Net Income(43.8M)(72.8M)(142.2M)(188.9M)(170.0M)(161.5M)
End Period Cash Flow43.7M284.3M85.3M230.8M265.4M147.7M

Day One Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Day One or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Day One's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Day stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
-0.13
β
Beta against Dow Jones0.44
σ
Overall volatility
2.24
Ir
Information ratio -0.06

Day One Volatility Alert

Day One Biopharmaceuticals exhibits very low volatility with skewness of 0.56 and kurtosis of -0.04. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Day One's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Day One's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

Day One Fundamentals Vs Peers

Comparing Day One's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Day One's direct or indirect competition across all of the common fundamentals between Day One and the related equities. This way, we can detect undervalued stocks with similar characteristics as Day One or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Day One's fundamental indicators could also be used in its relative valuation, which is a method of valuing Day One by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Day One to competition
FundamentalsDay OnePeer Average
Return On Equity-0.18-0.31
Return On Asset-0.25-0.14
Profit Margin(0.83) %(1.27) %
Operating Margin0.32 %(5.51) %
Current Valuation672.54 M16.62 B
Shares Outstanding100.85 M571.82 M
Shares Owned By Insiders16.98 %10.09 %
Shares Owned By Institutions94.97 %39.21 %
Number Of Shares Shorted17.29 M4.71 M
Price To Earning3.88 X28.72 X
Price To Book2.26 X9.51 X
Price To Sales12.05 X11.42 X
Gross Profit99.66 M27.38 B
EBITDA(206.06 M)3.9 B
Net Income(188.92 M)570.98 M
Cash And Equivalents394.86 M2.7 B
Cash Per Share5.38 X5.01 X
Total Debt408 K5.32 B
Debt To Equity0 %48.70 %
Current Ratio31.45 X2.16 X
Book Value Per Share5.51 X1.93 K
Cash Flow From Operations(146.85 M)971.22 M
Short Ratio15.50 X4.00 X
Earnings Per Share(0.97) X3.12 X
Target Price35.44
Number Of Employees17418.84 K
Beta-1.46-0.15
Market Capitalization1.23 B19.03 B
Total Asset376.05 M29.47 B
Retained Earnings(458.58 M)9.33 B
Working Capital345.77 M1.48 B
Net Asset376.05 M
Note: Disposition of 12048 shares by Bender Jeremy of Day One at 11.963 subject to Rule 16b-3 [view details]

Day One Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Day . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Day One Buy or Sell Advice

When is the right time to buy or sell Day One Biopharmaceuticals? Buying financial instruments such as Day Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Day One in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Banks Thematic Idea Now

Banks
Banks Theme
Large and small money and credit banks and credit services. The Banks theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banks Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Day One Biopharmaceu offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Day One's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Day One Biopharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Day One Biopharmaceuticals Stock:
Check out Day One Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.97)
Revenue Per Share
1.144
Return On Assets
(0.25)
Return On Equity
(0.18)
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.